Primary Immunodeficiency stem cell therapy — your questions answered (2026)

About stem cell therapy for Primary Immunodeficiency

Primary immunodeficiencies, also called inborn errors of immunity, comprise many genetic disorders with different infection, inflammatory, autoimmune and malignancy risks. Haematopoietic stem-cell transplantation (HSCT) can be established or potentially curative for selected severe diagnoses because it replaces the blood-forming immune system. This is not equivalent to an MSC infusion marketed for general immune support.

The evidence for Primary Immunodeficiency

Evidence and eligibility are diagnosis-, genotype-, donor- and centre-specific. HSCT may require conditioning and carries infection, graft failure, graft-versus-host disease and organ-toxicity risks; some disorders instead use immunoglobulin, antimicrobial, targeted immune or gene-based treatment. The NIAID GATA2-deficiency factsheet illustrates diagnosis-specific use of HSCT. It cannot validate a generic placental, stromal or exosome product.

Separate diagnostic genetics, donor search, product procurement, conditioning, admission, infection prophylaxis, long-term follow-up and complication care. Obtain a transplant centre and insurer decision for the exact diagnosis or a sponsor statement for a trial. Do not compare this pathway with a same-day commercial infusion by price alone.

Which immunodeficiencies are considered?

Cell therapy for Primary Immunodeficiency may be offered as an individualised programme, but regulatory status depends on the product, processing, indication and jurisdiction. It is currently approved (blood/immune only). Verify authorisation status, cell source, release testing and clinical evidence for the specific proposal.

Is this a transplant?

Schedules vary by the exact product, protocol, route, monitoring needs and clinical context. Request the proposed schedule and its evidence before making travel arrangements.

What is the assessment?

Eligibility depends on the protocol's inclusion and exclusion criteria and an appropriately qualified clinician's assessment. An online checklist cannot determine candidacy or replace medical advice.

EU cost?

The partner-published indicative range for an Primary Immunodeficiency programme is €3,000–€8,000 for treatment. Request a current written quotation and compare product, dose, visits, inclusions and follow-up before using country ranges as a benchmark.

Sources & further reading

We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.

• Open clinical trials for Primary Immunodeficiency (ClinicalTrials.gov) ↗
• Peer-reviewed research on PubMed ↗
• ISSCR patient guide — what to ask ↗
• FDA consumer warning on stem-cell therapies ↗
• EMA — advanced-therapy (ATMP) framework ↗
• Clinic perspective — Stem Plus on Primary Immunodeficiency ↗

← Back to Primary Immunodeficiency overview · Primary Immunodeficiency cost →